Clinical trials for advancing innovative interventions for neurodegenerative diseases
Cluster 1 - Health (Two stage - 2027) · HORIZON-RIA · Needs partners
What this call funds
This call funds clinical trials for new treatments of common neurodegenerative diseases, such as Alzheimer's or Parkinson's, excluding rare ones. Projects must combine a drug or active substance with another approach like lifestyle change, cognitive training or rehabilitation, and run early phase 1 or 2 clinical trials testing safety and effectiveness. It also expects use of digital tools like AI and wearables for monitoring patients, and strong engagement with patients, clinicians and regulators.
digital health · diagnostics · neuroscience · aging care · public health
Who wins this
A multidisciplinary clinical research consortium, potentially including hospitals, universities, SMEs and patient organisations, capable of running early phase clinical trials for neurodegenerative disease treatments combined with complementary therapeutic approaches.
Could you win this call?
Only the website is required.
The call in detail
- Indicative grant size
- €10M
- Funding model
- Budget-based. Reimbursement of actual eligible costs
- Submission
- Two-stage submission (short outline first, full proposal if invited)
- Cut-off dates (2)
- 17 Feb 2027 · 16 Sep 2027
- Type of action
- HORIZON Research and Innovation Actions
- Partners
- Required. The call asks for a consortium: a group applying together, typically 3+ organisations from 3+ countries.
- Also required
- Rare neurodegenerative diseases are excluded, and pharmacological interventions must be phase 1 and/or phase 2 clinical trials; any legal entity established in the United States is exceptionally eligible for funding under this topic.
- Eligible countries (45)
- Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Norway, Iceland, Switzerland, United Kingdom, Israel, Türkiye, Ukraine, Serbia, North Macedonia, Montenegro, Albania, Bosnia and Herzegovina, Kosovo, Georgia, Armenia, Moldova, Tunisia, New Zealand
Read the full conditions from the official call ›
General conditions 1. Admissibility Conditions, proposal page limit and layout Applicants submitting a proposal for a blind evaluation (see General Annex F) must not disclose their organisation names, acronyms, logos nor names of personnel in the proposal abstract and Part B of their first-stage application (see General Annex E). Admissibility conditions are described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes. Proposal page limits and layout are described in Part B of the Application Form available in the Submission System. 2. Eligible Countries Eligible countries are described in Annex B of the Work Programme General Annexes. A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide. 3. Other Eligibility Conditions In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding. If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used). Subject to restrictions for the protection of European communication networks. Other eligibility conditions are described in Annex B of the Work Programme General Annexes. 4. Financial and operational capacity and exclusion Financial and operational capacity and exclusion are described in Annex C of the Work Programme General Annexes. 5a. Evaluation and award: Award criteria, scoring and thresholds The first-stage proposals of this topic will be evaluated blindly. Award criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes. 5b. Evaluation and award: Submission and evaluation processes For the first stage, the thresholds for each criterion will be 4 (Excellence) and 4 (Impact). The overall threshold applying to the sum of the two individual scores will be set at a level that ensures the total requested budget of proposals admitted to stage 2 is as close as possible to four times the available budget, and not less than three and a half times the available budget. For the second stage, the thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold will be 12. Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual. 5c. Evaluation and award: Indicative timeline for evaluation and grant agreement Indicative timeline for evaluation and grant agreement are described in Annex F of the Work Programme General Annexes. 6. Legal and financial set-up of the grants The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5. Legal and financial set-up of the grants are described in Annex G of the Work Programme General Annexes. Specific conditions Specific conditions are described in the specific topic of the Work Programme. Application and evaluation forms and additional documents: Application and
Who has won calls like this
Organisations that most often win this call family · 44 past winners